Navigation Links
Radiation Oncology Services of America, Inc. Announces Formation of Scientific Advisory Board
Date:9/18/2008

NASHVILLE, Tenn., Sept. 18 /PRNewswire/ -- Radiation Oncology Services of America, Inc. (ROSA), a subsidiary of Ambulatory Services of America, Inc., announced today the inaugural meeting of its Scientific Advisory Board in Dallas, Texas on September 12, 2008. The Scientific Advisory Board is comprised of a diverse group of leaders in the radiation oncology field. It will advise ROSA on numerous scientific and clinical issues including research initiatives, practice patterns and emerging technologies. Board members include: Lawrence R. Coia, M.D., of East Coast Radiation Oncology Associates in Toms River, New Jersey; Dennis E. Hallahan, M.D., Chair of Radiation Oncology at Vanderbilt University in Nashville, Tennessee; Richard T. Hoppe, M.D., Chair of Radiation Oncology at Stanford University in Stanford, California; George E. Laramore, Ph.D., M.D., Chair of Radiation Oncology at the University of Washington in Seattle, Washington; Erich Randolph, M.D., of Atlanta Oncology Associates in Atlanta, Georgia; and J. Warner Ray, M.D., of Radiation Oncology Services in Atlanta, Georgia.

The inaugural meeting was led by Vincent W. Dennis, M.D., Senior Medical Advisor for Ambulatory Services of America, who said, "The Scientific Advisory Board will be a key instrument in positioning ROSA to improve its services to our radiation oncology partners and their patients now and in the future." Greg Merrill, Chief Operating Officer of ROSA, also participated and said, "The formation of the Scientific Advisory Board is another important step in ROSA's commitment to build a healthcare company of the highest quality using a physician-driven approach complemented by an experienced management team."

Tim Martin, President and Chief Executive Officer of ROSA's parent company, Ambulatory Services of America, said, "Physician leadership is essential to making sure that the best technology is available for the right patients at the right time. Bringing physician leaders together to be part of that important work is a key ROSA objective."

Radiation Oncology Services of America, Inc., headquartered in Brentwood, Tennessee owns interests in, operates and manages 13 radiation therapy facilities in five states. Ambulatory Services of America, Inc., headquartered in Brentwood, Tennessee, is a diversified health care services company that provides alternative site services in partnership with physicians. ASA, through its primary subsidiaries Radiation Oncology Services of America, Inc. and Innovative Dialysis Systems, Inc., owns interests in, operates and manages a total of more than 50 facilities providing radiation oncology services and dialysis services in ten states and the territory of Guam.


'/>"/>
SOURCE Radiation Oncology Services of America, Inc. (ROSA)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation Oncology Institute Campaign Raises $3 Million
2. Dr. Chad Levitt Joins North Georgia Radiation Oncology Center
3. Drug/radiation combo may help shrink established tumors
4. Grocery Manufacturers Association Strongly Supports U.S. Food & Drug Administration Decision on the Irradiation of Fresh Produce for Foodborne Pathogen Control
5. Targeted radiation therapy can control limited cancer spread
6. Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
7. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
8. Treating rare breast cancer with radiation therapy may lower recurrence rate
9. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Chicago-Area Radiation Oncology Facility
10. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas
11. Radiation for health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology: